TX-000045: a RXFP1 agonists Drug, Initially developed by Tectonic Operating Co., Inc., Now, its global highest R&D status is Phase 2, Mechanism: RXFP1 agonists(Relaxin receptor 1 agonists), Therapeutic Areas: Cardiovascular Diseases,Respiratory Diseases,